Traitement des syndromes myélodysplasiques

Treatment of MDS, which had remained for years purely symptomatic, has improved in recent years with better results of allogeneic SCT, the advent of hypomethylating agents (one of them, azacytidine, having demonstrated that it could improve survival in higher risk MDS), better knowledge of the utilization of ESAs, that appear capable to improve survival in lower risk MDS with anemia, the advant of « targeted » drugs like lenalidomide for MDS with del 5q, and finally better knowledge of iron overload due to transfusions an dits prevention by chelating agents.